Skip to main content

Table 5 Baseline characteristics of the treatment groups (per-protocol)

From: Effectiveness of a fortified drink in improving B vitamin biomarkers in older adults: a controlled intervention trial

Baseline characteristic Group P value
Placebo Active
  (n 33) (n 37)
Age (years) 64.6 (8.2) 64.4 (6.0) 0.892
Sex (% female) 54.5 59.5
Weight (kg) 72.5 (61.7–80.2) 72.8 (63.3–84.2) 0.881
Height (m) 1.69 (0.10) 1.68 (0.08) 0.535
BMI (kg/m2) 24.8 (23.0–28.3) 25.4 (23.4–29.5) 0.582
Waist (cm) 90.8 (81.5–100.3) 89.8 (81.5–105.1) 0.539
Hip (cm) 102.0 (97.8–107.3) 102.1 (99.6–109.1) 0.844
Waist:hip 0.88 (0.09) 0.90 (0.10) 0.455
Systolic BP (mmHg) 129.2 (20.0) 127.2 (21.1) 0.694
Diastolic BP (mmHg) 76.0 (9.2) 75.2 (11.5) 0.765
Plasma total 25(OH)D (nmol/L) 59.6 (49.3–73.5) 58.8 (37.6–65.4) 0.500
Serum homocysteine (µmol/L) 10.5 (9.6–12.6) 11.6 (10.0–14.8) 0.035
Serum folate (nmol/L) 18.2 (14.1–24.0) 15.5 (12.5–21.6) 0.177
Serum vitamin B12 (pmol/L) 344 (243–439) 310 (246–413) 0.374
Plasma PLP (vitamin B6 (nmol/L) 63.9 (49.1–79.8) 59.4 (45.5–79.4) 0.388
Riboflavin (EGRac) 1.28 (1.22–1.34) 1.34 (1.25–1.41) 0.088
  1. Data presented as mean (SD) and median (IQR). Per-protocol analysis includes all participants who completed the 16-week intervention. P value of differences between groups, p < 0.05 considered statistically significant. BP, blood pressure; EGRac, erythrocyte glutathione reductase activation coefficient; PLP, Pyridoxal 5′-phosphate